Association between acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in critically ill patients

Kayeong Chun¹, Wookyung Chung¹,², Ae Jin Kim³, Han Ro¹,², Jae Hyun Chang¹,², Hyun Hee Lee¹,² & Ji Yong Jung¹,²,³

Procalcitonin (PCT) is a useful marker for the diagnosis of systemic inflammatory response syndrome. In addition, PCT is affected by renal function. However, few studies have investigated the relationship between PCT and the development of acute kidney injury (AKI). Hence, we investigated whether serum PCT levels at the time of admission were associated with the development of AKI and clinical outcomes. A total of 790 patients in whom PCT was measured on admission to the intensive care unit (ICU) were analyzed retrospectively. We attempted to investigate whether serum PCT levels measured at the time of admission could be used as a risk factor for the development of AKI in septic and nonseptic patients or as a risk factor for all-cause mortality, and diagnostic usefulness of PCT was further assessed.

Serum PCT levels were significantly higher in patients with AKI than in those without AKI (p < 0.001). After multivariable adjustment for clinical factors, laboratory findings, and comorbidities, PCT as a continuous variable showed a significant association with AKI (OR 1.006, 95% CI [1.000–1.011]; P = 0.035). However, PCT was not effective in predicting mortality. The cut-off value of PCT for the prediction of AKI incidence was calculated to be 0.315 ng/ml, with sensitivity and specificity of 60.9% and 56.9%, respectively. The odds ratios (ORs) from an equation adjusted for optimum thresholds of PCT levels for developing AKI with and without sepsis were 2.422 (1.222–4.802, P = 0.011) and 1.798 (1.101–2.937, P = 0.019), respectively. However, there were no absolute differences between the pre- and posttest probabilities after including the PCT value for AKI development. This study suggests that the PCT value was higher in AKI patients than in non-AKI patients, but PCT measurement at the time of admission did not improve the prediction model for AKI.

Acute kidney injury (AKI) occurs in 5 to 7% of all hospitalized patients¹. With a frequency of 36 to 67%, however, AKI occurs more frequently in critically ill patients²-⁴. The development of AKI in patients in the intensive care unit (ICU) varies depending on their underlying etiology (e.g., sepsis, trauma, major surgery, or exposure to contrast medium), but once AKI occurs, the results are associated with significant morbidity and high mortality⁵.

To date, many studies have tried to prevent the occurrence of AKI and find biomarkers to predict AKI⁶-⁸. In recent years, various laboratory parameters, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (L-FABP), interleukin-18 (IL-18), and cystatin C, have been proposed as potential biomarkers of AKI⁶-⁸. Procalcitonin (PCT) is a 116-amino-acid precursor of calcitonin with a molecular weight of 13,600 Da. PCT is undetectable, or only barely detectable, in healthy individuals. However, in cases of sepsis, PCT levels can fluctuate in the range of 10 to 100 ng/ml and are accompanied by elevations in cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6)⁹. Recently, it has been reported that renal function is a major determinant of PCT levels, and thus, different thresholds should be applied according to impairments in renal function¹⁰-¹³. However, few studies have investigated the relationship between PCT levels and AKI.
Therefore, we investigated whether serum PCT levels at the time of ICU admission were associated with the development of AKI and clinical outcomes in critically ill patients.

**Results**

**Baseline characteristics.** A total of 790 (478 males) of 12,051 screened subjects were enrolled as eligible study participants (Fig. 1). The mean age was 60.3 ± 17.1 years. Basal characteristics are described in Table 1. A total of 33.7% (266 of 790) of patients developed AKI. Furthermore, 41.7% (111 of 266) of patients with AKI and 32.8% (172 of 524) of patients without AKI had sepsis. AKI patients were more likely to have sepsis than those in the non-AKI group (P < 0.014). These patients also commonly had chronic kidney disease (CKD), diabetes mellitus (DM), hypertension (HTN), chronic liver disease (CLD), and previous cardiovascular disease (CVD). Patients who developed AKI had significantly higher serum creatinine and hsCRP levels and lower blood pH than did patients who did not develop AKI. PCT levels in the AKI group were significantly higher than those in the non-AKI group (P < 0.001).

**The development of AKI and serum PCT levels at the time of admission.** Of the 790 patients, 266 developed AKI, with severity stages as follows: stage 1 (N = 172), stage 2 (N = 56), and stage 3 (N = 38). In the univariate analyses using PCT as a continuous variable, PCT at the time of admission was significantly associated with the development of AKI (odds ratio [OR; 1.007], 95% confidence interval [CI; 1.003–1.011]; P = 0.002; Table 2). After multivariable adjustment for clinical factors, laboratory findings, and comorbidities, PCT showed a significant association with AKI (OR 1.006, 95% CI [1.000–1.011]; P = 0.035; Table 2).

**Risk factors for 30-day mortality.** Of the 790 patients used for total analysis, 99 patients died within 30 days of observation. Of the patients with 30-day mortality, 32 patients were in the sepsis group (67 patients were in the nonsepsis group). The mortality results from the multivariable Cox proportional regression analyses (using the same variables as model 4 of AKI) with serum PCT level as a continuous variable demonstrated that the hazard ratio (HR) of PCT for all-cause mortality was 0.999 (95% CI, 0.991–1.007; P = 0.798). The HR of mortality with a cut-off value of PCT > 0.315 ng/ml used in the AKI prediction was 0.968 (95% CI, 0.586–1.597; P = 0.898). These results were not significant in either the sepsis group (HR, 1.991; 95% CI, 0.695–5.702; P = 0.200) or the nonsepsis group (HR, 0.876; 95% CI, 0.474–1.618; P = 0.200).

**Correlation analyses between PCT and other variables.** Correlation analyses showed a positive correlation between PCT and hsCRP (p = 0.428, P < 0.001), AKI (p = 0.116, P = 0.001), and sepsis (p = 0.130, P < 0.001, Table 3).

**Determining diagnostic value of PCT in predicting AKI.** We attempted to adjust the predictive cut-off value of PCT at varying levels. In Table 4, sensitivity, specificity, AUC, and likelihood ratio of PCT values for the prediction AKI at cut-off values of clinical condition (0.05, 0.5, 2, 10 ng/ml) were demonstrated. All thresholds were inadequate for clinical applications due to low sensitivity, specificity and AUC. Therefore, we tried to find the optimal threshold by calculation using the Youden method. In this study population, the cut-off value for PCT (0.315 ng/ml) obtained by the receiver operating characteristic (ROC) curve analysis was calculated as the optimal model for the prediction of AKI (AUC 0.589; sensitivity 60.9%; specificity 56.9%; Table 4).

In the univariate analyses, PCT > 0.315 ng/ml at the time of admission was significantly associated with the development of AKI (OR: 2.422, 95% CI: 1.222–4.802; P = 0.011). In the nonsepsis group, the serum PCT level was also related to the development of AKI (OR 1.912, 95% CI [1.299–2.814]; P = 0.001; Table 5). Furthermore, we analyzed the relationship between PCT and AKI in each group with and without sepsis. In the sepsis group, PCT > 0.315 ng/ml at the time of admission remained a significant independent risk factor for AKI (OR 2.422, 95% CI [1.222–4.802]; P = 0.011). In the nonsepsis group, the serum PCT level was also related to the development of AKI (OR 1.798, 95% CI [1.101–2.937]; P = 0.019; Table 5).

To assess the diagnostic usefulness of PCT, we examined the differences between pre- and posttest probability. The likelihood ratio of a positive test result [sensitivity/(1-specificity)] was 1.413, and the likelihood ratio of
a negative test result \([1 - \text{sensitivity}] / \text{specificity}\) was 0.687. Using the 36–67% prevalence of AKI in critically ill patients from previous reports 2–4, we estimated the probabilities of AKI to be 44–74% following a positive test result (PCT > 0.315 ng/ml) and 28–58% following a negative test result (PCT \(\leq 0.315\) ng/ml). Interactive graphical presentation was illustrated by the Clinical Accuracy and Utility tool by Allen et al.14 (Fig. 2).

**Discussion**

This study does not support the usefulness of adding PCT levels to existing models for predicting the occurrence of AKI in critically ill patients in the ICU. The PCT value was higher in the AKI group, and it should be noted that careful attention is needed to interpret the clinical significance of PCT in critically ill patients with reduced renal function. However, despite the association between PCT and AKI, we were unable to establish the complete enhancement of AKI prediction by adding PCT to the existing AKI risk factors.

The kinetics of PCT, including the elimination route or mechanism, are not fully known. However, considering its low molecular weight of 13,600 Da, impaired renal function is thought to affect PCT levels. In previous studies, end-stage renal disease patients had a mean serum PCT value of 0.69 ± 0.81 ng/ml before dialysis and presented higher than the standard value of 0.5 ng/ml in 57% of patients15. The mean serum PCT level decreased

### Table 1. Baseline characteristics

| Demographic | Total (N = 790) | AKI (N = 266) | No AKI (N = 524) | P |
|-------------|----------------|--------------|-----------------|---|
| Age, year   | 60.3 ± 17.1    | 62.4 ± 16.1  | 59.3 ± 17.6     | 0.012 |
| Male gender, n (%) | 478 (60.5%) | 159 (59.8%) | 319 (60.9%) | 0.764 |

| Medical history | Total (N = 790) | AKI (N = 266) | No AKI (N = 524) | P |
|----------------|----------------|--------------|-----------------|---|
| CKD, n (%)     | 59 (7.5%)     | 39 (14.7%)   | 20 (3.8%)       | <0.001 |
| DM, n (%)      | 84 (10.6%)    | 59 (22.2%)   | 25 (4.8%)       | <0.001 |
| HTN, n (%)     | 133 (16.8%)   | 88 (33.1%)   | 45 (8.6%)       | <0.001 |
| CVD, n (%)     | 150 (19.0%)   | 86 (32.3%)   | 64 (12.2%)      | <0.001 |
| CLD, n (%)     | 27 (3.4%)     | 15 (5.6%)    | 12 (2.3%)       | 0.014 |
| COPD, n (%)    | 33 (4.2%)     | 16 (6.0%)    | 17 (3.2%)       | 0.066 |
| Asthma, n (%)  | 32 (4.1%)     | 18 (6.8%)    | 14 (2.7%)       | 0.006 |

| AKI risk factors | Total (N = 790) | AKI (N = 266) | No AKI (N = 524) | P |
|------------------|----------------|--------------|-----------------|---|
| Sepsis, n (%)    | 283 (35.8%)   | 111 (41.7%)  | 172 (32.8%)     | 0.014 |
| Transfusion, n (%) | 360 (45.6%) | 148 (55.6%) | 212 (40.5%)     | <0.001 |
| Ventilator care, n (%) | 520 (65.8%) | 184 (69.2%) | 336 (64.1%)     | 0.157 |

| Medications | Total (N = 790) | AKI (N = 266) | No AKI (N = 524) | P |
|-------------|----------------|--------------|-----------------|---|
| RAS blockers, n (%) | 76 (9.6%) | 53 (19.9%) | 23 (4.4%) | <0.001 |
| CCB, n (%)   | 59 (7.5%)     | 38 (14.3%)   | 21 (4.0%)       | <0.001 |
| Beta-blocker, n (%) | 64 (8.1%) | 45 (16.9%) | 19 (3.6%) | <0.001 |
| Diuretics, n (%) | 68 (8.6%) | 45 (16.9%) | 23 (4.4%) | <0.001 |
| Inotropics, n (%) | 543 (68.7%) | 207 (77.8%) | 336 (64.1%) | <0.001 |
| Aminoglycoside, n (%) | 40 (5.1%) | 8 (3.0%) | 32 (6.1%) | 0.060 |
| Vancomycin, n (%) | 114 (14.4%) | 41 (15.4%) | 73 (13.9%) | 0.575 |
| Colistin, n (%) | 22 (2.8%)     | 11 (4.1%)    | 11 (2.1%)       | 0.100 |
| NSAID, n (%)   | 436 (55.2%)   | 134 (50.4%)  | 302 (57.6%)     | 0.053 |
| Contrast, n (%) | 63 (8.0%)     | 20 (7.5%)    | 43 (8.2%)       | 0.736 |
| Chemotherapy, n (%) | 6 (0.8%) | 1 (0.4%) | 5 (1.0%) | 0.670 |

| Laboratory findings* | Total (N = 790) | AKI (N = 266) | No AKI (N = 524) | P |
|----------------------|----------------|--------------|-----------------|---|
| PCT (ng/ml)          | 0.3 (0.1, 3.6) | 0.7 (0.1, 7.1) | 0.2 (0.1, 2.7) | <0.001 |
| Creatinine (mg/dl)   | 1.1 (0.8, 1.4) | 1.3 (1.0, 2.1) | 1.0 (0.7, 1.2) | <0.001 |
| hsCRP (mg/dl)        | 1.6 (0.1, 11.1) | 2.5 (0.2, 14.3) | 1.3 (0.1, 9.5) | 0.005 |
| WBC (10³/mm³)        | 12.7 (9.1, 18.0) | 13.1 (9.8, 18.5) | 12.5 (8.9, 17.8) | 0.116 |
| pH                   | 7.3 (7.2, 7.4) | 7.3 (7.3, 7.4) | 7.4 (7.2, 7.4) | <0.001 |
| pCO2 (mmHg)          | 35 (28, 47)    | 35 (27, 52)   | 35 (29, 46)     | 0.208 |
| SpO2 (mmHg)          | 70 (47, 101)   | 68 (43, 95)   | 72 (48, 103)    | 0.153 |

| Severity of illness* | Total (N = 790) | AKI (N = 266) | No AKI (N = 524) | P |
|----------------------|----------------|--------------|-----------------|---|
| SOFA score           | 6.0 (4.0, 8.0) | 6.0 (4.0, 8.0) | 6.0 (4.0, 8.0) | 0.287 |

---

*Variables are expressed as the median and IQR.
Table 2. Prognostic implication of PCT as a continuous variable on AKI development and 30-day mortality in critically ill patients. Model 1: adjusted for demographics (age >65, female sex). Model 2: adjusted for demographics, and comorbidities (model 1 + CKD, DM, HTN, CVD, CLD, COPD, and asthma). Model 3: adjusted for demographics, comorbidities, and AKI risk factors (model 2 + RAS blockers, inotropes, transfusion, ventilator, aminoglycosides, vancomycin, colistin, amphotericin, NSAID, contrast media, and chemotherapy). Model 4: adjusted for demographics, comorbidities, AKI risk factors, and laboratory findings (model 3 + Hb, hsCRP, albumin, WBC, and SOFA score). Abbreviations: OR, odds ratio; PCT, procalcitonin; AKI, acute kidney injury; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; CVD, cardiovascular disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; RAS, renin-angiotensin-aldosterone system; CCB, calcium channel blocker; NSAID, nonsteroidal anti-inflammatory drug; hsCRP, highly sensitive C-reactive protein; WBC, white blood cell; SOFA, Sequential Organ Failure Assessment.

| PCT | hsCRP | Age | Sex | AKI | Sepsis | Mortality |
|-----|-------|-----|-----|-----|-------|----------|
| PCT | ρ   | 1   | 0.428 | 0.107 | 0.028 | 0.116 | 0.130 | 0.054 |
| P   | —   | <0.001 | 0.003 | 0.437 | 0.001 | <0.001 | 0.131 |
| hsCRP | ρ | 1   | 0.241 | 0.033 | 0.072 | 0.278 | 0.065 |
| P   | —   | <0.001 | 0.359 | 0.042 | <0.001 | 0.069 |
| Age | ρ | 1   | 0.131 | 0.087 | 0.164 | 0.001 |
| P   | —   | <0.001 | 0.014 | 0.001 | 0.967 |
| Sex | ρ | 1   | 0.011 | 0.039 | — | 0.059 |
| P   | —   | 0.765 | 0.273 | 0.097 |
| AKI | ρ | 1   | 0.088 | 0.012 |
| P   | —   | 0.014 | 0.730 |
| Sepsis | ρ | 1   | 0.024 |
| P   | —   | 0.505 |
| Mortality | ρ | 1   | — |
| P   | —   | — |

Table 3. Cross-sectional correlation analyses between PCT and other variables. Abbreviations: PCT, procalcitonin; hsCRP, highly sensitive C-reactive protein; AKI, acute kidney injury.

| PCT (ng/ml) | Clinical condition | PCT threshold (ng/ml) | AUC | Sensitivity | 95% CI | Specificity | 95% CI | +LR | −LR |
|-------------|--------------------|-----------------------|-----|-------------|-------|-------------|-------|-----|-----|
| <0.05       | Healthy            |                       |     |             |       |             |       |     |     |
| 0.05–0.5    | Local infection    | 0.05                  | 0.561 | 0.744 | 0.688–0.796 | 0.378 | 0.336–0.421 | 1.196 | 0.677 |
| 0.5–2.0     | Systemic infection (sepsis) | 0.5 | 0.573 | 0.549 | 0.487–0.610 | 0.597 | 0.554–0.640 | 1.362 | 0.755 |
| 2.0–10      | Severe sepsis      | 2.0                   | 0.549 | 0.380 | 0.318–0.437 | 0.721 | 0.631–0.759 | 1.362 | 0.860 |
| >10         | Septic shock       | 10                    | 0.544 | 0.229 | 0.180–0.285 | 0.863 | 0.830–0.891 | 1.672 | 0.893 |
| Cut-off valueb |                  | 0.315                  | 0.589 | 0.609 | 0.548–0.668 | 0.569 | 0.525–0.612 | 1.413 | 0.687 |

Table 4. Summary of PCT values to predict AKI. Abbreviations: PCT, procalcitonin; AUC, area under curve; +LR, positive likelihood ratio; −LR, negative likelihood ratio. bCommonly used PCT threshold in clinical practice. cThreshold developed using the Youden method.
significantly to 83 ± 25% after high-flux dialysis, whereas no change in PCT concentration occurred after low-flux dialysis. In addition, PCT was elevated in patients on continuous ambulatory peritoneal dialysis (median of 1.18 ng/ml). Several studies have demonstrated a significant positive correlation between PCT and creatinine and a significant negative correlation between PCT and estimated glomerular filtration rate (eGFR). These findings suggest that PCT is partially removed via the kidney and is therefore dependent on renal function. The results of the current investigation also imply that PCT may be influenced by renal function. According to existing research, the diagnostic accuracy of PCT showed significantly lower sensitivity and specificity to the reliability of bacterial infections in patients with renal impairment. Because renal function is a major determinant of PCT levels, higher cut-off values should be applied to patients with impaired renal function.

Table 5. Prognostic implication of PCT as a cut-off value on AKI development in patients with or without sepsis. Model 1: adjusted for demographics (age > 65, female sex). Model 2: adjusted for demographics, and comorbidities (model 1 + CKD, DM, HTN, CVD, CLD, COPD, and asthma). Model 3: adjusted for demographics, comorbidities, and AKI risk factors (model 2 + RAS blockers, inotropes, transfusion, ventilator, aminoglycosides, vancomycin, colistin, amphotericin, NSAID, contrast media, and chemotherapy). Model 4: adjusted for demographics, comorbidities, AKI risk factors, and laboratory findings (model 3 + Hb, hsCRP, albumin, WBC, and SOFA score). Abbreviations: OR, odds ratio; PCT, procalcitonin; AKI, acute kidney injury; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; CVD, cardiovascular disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; RAS, renin-angiotensin-aldosterone system; CCB, calcium channel blocker; NSAID, nonsteroidal anti-inflammatory drug; hsCRP, highly sensitive C-reactive protein; WBC, white blood cell; SOFA, Sequential Organ Failure Assessment.

Figure 2. Pre- and posttest probability after PCT for AKI development in critically ill patients. Posttest probability was calculated based on pretest probability and the likelihood ratio: posttest odds = pretest odds x likelihood ratio. The graph shows that for a patient with a pretest probability of AKI of 36–67%, the posttest probability will be 44–74% following a positive test result (PCT > 0.315 ng/ml) and 28–58% following a negative test result (PCT ≤ 0.315 ng/ml).
the discrepancy in the frequency of comorbidities between the AKI and non-AKI groups may also contribute to differences in PCT levels, regardless of sepsis.

The pathophysiological mechanism explaining the relationship between serum concentrations of PCT and AKI is still unclear. Various inflammatory responses have been suggested as a possible mechanism for the development of AKI. Experimental data have confirmed that bacterial toxins and other mediators can induce PCT. PCT acts as a chemoattractant in the inflammatory area, directly attracting more monocytes. PCT is initially produced in adherent monocytes that later contribute to the marked increase in circulating PCT by recruiting parenchymal cells when they are in direct contact with activated monocytes. The expression of PCT mRNA by peripheral blood mononuclear cells is stimulated by LPS or other toxins released by microbes. Additionally, it is suggested that an indirect pathway induced through cell-mediated host responses caused by inflammatory cytokines (e.g., IL-1β, IL-6, and TNF-α) plays a pivotal role in AKI. Another possible mechanism represents the direct toxic effect of PCT on mesangial cells. This study showed that mesangial cells could be destroyed by PCT through increased synthesis of IL-6, iNOS, and TNF-α, inducing disruption of actin microfilaments and apoptosis. This result reflects the possibility of PCT as a toxic mediator of AKI. In some studies, PCT elevations have been shown to affect impaired renal function, but there is a lack of evidence as to whether PCT can be used as a predictive marker for AKI. Based on the above-described mechanism, we analyzed the diagnostic value of AKI by dividing the patient group according to various levels of PCT (PCT: 0.05, 0.5, 2, 10 ng/ml), which was not clinically useful. In addition, when calculating the predictive cut-off value (PCT > 0.315 ng/ml) and analyzing the results, the association between the PCT cut-off value and subsequent AKI development was significant regardless of sepsis. However, the posttest probability did not show a significant improvement. Therefore, if a critically ill patient exhibits PCT elevation when an AKI occurs during treatment, other causes should be considered rather than a change due to kidney dysfunction.

Unlike other studies, elevations in PCT were not associated with mortality in our study. In a study comparing mortality by serial PCT measurement, mortality at day 28 increased by two fold in contrast to mortality at day 4, when PCT did not decrease by more than 80%. Our study did not conclude that PCT and mortality were statistically correlated, even though the number of patients who died before 30 days was high. This may be likely due to the PCT levels and the high severity and comorbidity of the patients upon admission. This hypothesis is difficult to confirm because our study measured PCT once at admission. There was no difference in the SOFA score between the AKI and non-AKI groups (Table 1), and the score was similar when we divided the groups according to the presence or absence of sepsis and death (data not shown). We assume that the reason for the lack of correlation between PCT and mortality is that the severity of illness does not vary with mortality, which needs to be verified through serial measurement of PCT.

The study has several limitations. First, this is a retrospective study involving a small sample size in a single center. Second, we did not examine other AKI biomarkers, such as NGAL or cystatin C. Therefore, it is not possible to determine the diagnostic accuracy of PCT in comparison to another AKI biomarker. Third, we only examined PCT levels upon ICU admission and therefore cannot address the variability in inflammatory markers during the course of the study. To fully understand the relationship between changes in PCT levels and patient prognosis, sequential blood sampling may be needed to investigate the effectiveness of therapeutic strategies and the prognostic role of PCT.

In summary, serum PCT levels were significantly higher in patients with AKI than in those without AKI, and the most appropriate PCT cut-off value was calculated and analyzed. There was an association between PCT and AKI, but it was insufficient to provide diagnostic usefulness. Therefore, the use of PCT for the clinical diagnosis of sepsis in patients with decreased renal function requires more caution than usual, and the elevation of PCT in patients with AKI may be necessary to identify other infective causes other than renal dysfunction.

In conclusion, this study suggests that the PCT value was higher in AKI patients than in non-AKI patients, but the PCT measurement at the time of admission did not improve the prediction model for AKI in critically ill patients.

Methods

Study design and participants. This study was a retrospective study to determine the role of PCT in the development of AKI in critically ill patients in the ICU. From January 2009 to December 2013, ICU inpatients in Gachon University Gil Medical Center who had PCT levels measured at the time of admission were analyzed. A total of 12,051 patients were examined. Patients whose age was 18 years or younger (N = 2,321), who were transferred to the ICU after initial hospitalization (N = 7,254), who had already received dialysis before the PCT measurement (N = 991), or whose timing of the PCT measurements was not consistent with baseline parameter measurements (N = 695) were excluded from the study. Therefore, 790 patients were finally analyzed. This study was approved by the Institutional Review Board (IRB) of our institution (GAIRB2016-086). Because this study did not involve any further intervention in the retrospective analysis, the need for obtaining consent was waived by the IRB.

Variables. Demographics (age, sex, comorbidities, and prescribed medication) and blood test results (blood gas analysis, white blood cell count [WBC], levels of hemoglobin [Hb], hematocrit [Hct], platelets, blood urea nitrogen [BUN], creatinine, albumin, and highly sensitive C-reactive protein [hsCRP]) were recorded as baseline data at the time of admission. Clinical data (mechanical ventilation, sepsis status at admission, use of inotropes, and blood transfusion) and comorbidities (history of CKD, DM, pre-existing HTN, CVD, CLD, asthma, and chronic obstructive pulmonary disease [COPD]) prior to ICU admission treatment were recorded according to the ICD-10 diagnostic criteria. The use of drugs with potential renal toxicity (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, nonsteroidal anti-inflammatory drugs), the use of contrast media within 24 hours of developing AKI, and the use of anticancer drugs with a platinum-based regimen within the last
6 months were also investigated. Severity of illness was assessed using the Sequential Organ Failure Assessment (SOFA) scoring system. The eGFR was calculated according to the four-variable Modification of Diet in Renal Disease (MDRD) Study formula. Cardiovascular risk factors were assessed at the beginning of the observation. Patients were classified according to the ICD-10 code for baseline disease. In addition, hypertension was defined as a blood pressure of >140/90 mmHg measured at least 2 times and a prescription of antihypertensive agents. CVD history was defined as any previous myocardial infarction, angina pectoris, ischemic heart disease, cerebrovascular accident, atrial fibrillation or flutter, or peripheral atherosclerotic vascular disease. DM was defined as the use of an oral anti-diabetic agent or insulin. CKD was defined as having evidence of kidney damage (proteinuria estimated by dipstick as trace or greater) with underlying disease or eGFR less than 60 mL/min/1.73 m².

Outcomes. The primary outcome was the development of AKI. We followed the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for the diagnosis and classification of AKI, which classifies renal damage due to AKI based on serum creatinine levels. The baseline serum creatinine was measured at the time of admission. The diagnostic criteria for AKI were defined as an absolute increase in serum creatinine value ≥ 0.3 mg/dl or a 50% relative increase from baseline value within 48 hours. The risk factors for AKI were also assessed at the time of ICU admission. The secondary outcome was 30-day mortality rate. The diagnosis of sepsis (including severe sepsis and septic shock) was defined by the American college of chest physicians/society of critical care medicine (ACCP/SCCM) consensus conference committee.

Statistical analysis. The data are presented as the mean ± standard deviation for continuous variables and as proportions for categorical variables. Variables with nonnormal distributions are expressed as the medians [interquartile range (IQR)] based on variable distributions using histograms and Kolmogorov-Smirnov test. A chi-squared test was used to compare categorical variables. Comparisons between the normally and nonnormally distributed continuous variables were performed using Student's t-tests and Mann-Whitney U tests, respectively.

We first analyzed the diagnostic value of PCT as a continuous variable and then determined the PCT cut-off level for predicting AKI. We used the Youden index of the ROC curve. The risk factors associated with AKI were analyzed using multivariable logistic regression analyses to obtain the odds ratio (OR) and 95% confidence interval (CI). Multiple Cox regression models were used to analyze the risk factors associated with 30-day mortality and calculate the HRs. As a stepwise regression model, we applied the method used in our previous study and analyzed it as follows. First, the model was performed using demographic variables only (model 1). Second, comorbidities were added to model 1 for model 2 analysis. Third, we analyzed the AKI risk factors in addition to model 2 to create model 3, and finally, we added laboratory data and SOFA scores to model 3 to create model 4.

In addition, we attempted to determine whether there is a clinical value worth considering in the diagnosis according to the results of a previous study. The diagnostic values were evaluated by comparing the pre- and postprobabilities of the analysis results with the model containing only existing risk factors and the model with PCT added.

Differences at P < 0.05 were considered statistically significant. For the analysis, commercially available SPSS 20.0 software (IBM SPSS Inc., Armonk, NY, USA) and MedCalc 17.2 (MedCalc Software, Ostend, Belgium) were used.

References
1. Chertow, G. M., Burdick, E., Honour, M., Bonventre, J. V. & Bates, D. W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16, 3365–3370, https://doi.org/10.1681/asn.2004090740 (2005).
2. Pruchnicki, M. C. & Dasta, J. F. Acute renal failure in hospitalized patients: part I. Ann Pharmacother 36, 1261–1267, https://doi.org/10.1345/aph.1A339 (2002).
3. Dennen, P., Douglas, I. S. & Anderson, R. Acute kidney injury in the intensive care unit: an update and primer for the intensivist. Crit Care Med 38, 261–275, https://doi.org/10.1097/CCM.0b013e3181fb065 (2010).
4. Pruchnicki, M. C. & Dasta, J. F. Acute renal failure in hospitalized patients: part II. Ann Pharmacother 36, 1430–1442, https://doi.org/10.1345/aph.1A340 (2002).
5. Vaidya, V. S., Ferguson, M. A. & Bonventre, J. V. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 48, 463–493, https://doi.org/10.1146/annurev.pharmtox.48.113006.094615 (2008).
6. de Geus, H. R., Betjes, M. G. & Bakker, J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J 5, 102–110, https://doi.org/10.1093/ckj/sfs008 (2012).
7. Kim, H., Huh, M., Cruz, D. N., Moon, H. W. & Yun, Y. M. Plasma neutrophil gelatinase-associated lipocalin as a biomarker for acute kidney injury in critically ill patients with suspected sepsis. Clin Biochem 46, 1414–1418, https://doi.org/10.1016/j.clinbiochem.2013.05.069 (2013).
8. Hiruma, T. et al. Mortality prediction by acute kidney injury biomarkers in comparison with serum creatinine. Biomarkers 19, 646–651, https://doi.org/10.3109/1354733X.2014.968299 (2014).
9. Prucha, M., Bellingan, G. & Zazula, R. Sepsis biomarkers. Clin Chim Acta 440, 97–103, https://doi.org/10.1016/j.cca.2014.11.012 (2015).
10. Nakamura, Y. et al. Potential use of procalcitonin as biomarker for bacterial sepsis in patients with or without acute kidney injury. J Infect Chemother 21, 257–263, https://doi.org/10.1016/j.jiac.2014.12.001 (2015).
11. Herget-Rosenthal, S. et al. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant 16, 975–979 (2001).
12. Steinbach, G., Bolke, E., Grunert, A., Storck, M. & Orth, K. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr 116, 849–853 (2004).
13. El-Sayed, D., Grotts, J., Golgert, W. A. & Sugar, A. M. Sensitivity and specificity of procalcitonin in predicting bacterial infections in patients with renal impairment. Open Forum Infect Dis 1, ofu068, https://doi.org/10.1093/ofid/ofu068 (2014).
14. Fanshawe, T. R. et al. Interactive visualisation for interpreting diagnostic test accuracy study results. BMJ Evid Based Med 23, 13–16, https://doi.org/10.1136/bmjebm-2017-110862 (2018).
15. Level, C. et al. Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial Transplant 16, 980–986 (2001).
16. Park, J. H. et al. Clinical relevance of procalcitonin and C-reactive protein as infection markers in renal impairment: a cross-sectional study. Crit Care 18, 640, https://doi.org/10.1186/s13054-014-0640-8 (2014).
17. Yang, E. A., Park, J. S., Cho, M. H. & Lee, S. W. Clinical Usefulness of Serum Procalcitonin as a Biomarker of Acute Pyelonephritis. *Korean J Nephrol* 29, 716–724 (2010).

18. Amour, J. et al. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. *Crit Care Med* 36, 1147–1154, https://doi.org/10.1097/CCM.0b013e3181692966 (2008).

19. Meisner, M., Adina, H. & Schmidt, J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. *Crit Care* 10, R1, https://doi.org/10.1186/cc9310 (2006).

20. Okusa, M. D. The inflammatory cascade in acute ischemic renal failure. *Nephron* 90, 133–138, https://doi.org/10.1159/000049032 (2002).

21. Lemay, S., Rabb, H., Postler, G. & Singh, A. K. Prominent and sustained up-regulation of gp130-signaling cytokines and the chemokine MIP-2 in murine renal ischemia-reperfusion injury. *Transplantation* 69, 939–963 (2000).

22. Araújo, M., Doi, S. Q., Palant, C. E., Nylen, E. S. & Becker, K. L. Procalcitonin induced cytotoxicity and apoptosis in mesangial cells: implications for septic renal injury. *Inflamm Res* 62, 887–894, https://doi.org/10.1007/s00011-013-0646-8 (2013).

23. Linscheid, P. et al. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. *Crit Care Med* 32, 1715–1721 (2004).

24. Chang, C. F. et al. Gene polymorphisms of interleukin-10 and tumor necrosis factor-alpha are associated with contrast-induced nephropathy. *Am J Physiol Renal Fluid Electrolyte Physiol* 293, F1126–F1132 (2007).

25. Wiedermann, F. I. et al. Migration of human monocytes in response to procalcitonin. *Crit Care Med* 30, 1112–1117 (2002).

26. Oberhofer, M. et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. *J Lab Clin Med* 134, 49–55 (1999).

27. Ramesh, G. & Reeves, W. B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. *J Clin Invest* 110, 835–842, https://doi.org/10.1172/jci15606 (2002).

28. Jensen, J. U. et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. *Critical care medicine* 34, 2596–2602 (2006).

29. Schuetz, P. et al. Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results from the Multicenter Procalcitonin MoNitoring Sepsis (MOSES) Study. *Crit Care Med* 45, 781–789, https://doi.org/10.1097/ccm.0000000000000232 (2017).

30. Vincent, J. L. et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med* 22, 707–710 (1996).

31. Levey, A. S. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 130, 461–470 (1999).

32. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 39, S1–S266 (2002).

33. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl* 2, 1–138 (2012).

34. Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 101, 1644–1655 (1992).

35. Youden, W. J. Index for rating diagnostic tests. *Cancer* 3, 32–35 (1950).

36. Lim, H. J. et al. Renin-Angiotensin-Aldosterone System Blockade in Critically Ill Patients Is Associated with Increased Risk for Acute Kidney Injury. *Tohoku J Exp Med* 238, 17–23, https://doi.org/10.1620/jem.238.17 (2016).

37. Jaeschke, R., Guyatt, G. H. & Sackett, D. L. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. *JAMA* 271, 703–707 (1994).

**Author Contributions**

J.Y.J. conceived and designed the study. K.C., W.C. and J.Y.J. analyzed the data. K.C. and J.Y.J. wrote the manuscript. K.C., W.C., A.J.K., H.K., H.R., J.H.C., H.H.L. and J.Y.J. revised the manuscript. All authors reviewed the manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

*Open Access* This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019